Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimers patients--an open-label trial

International Journal of Geriatric Psychiatry, 04/19/2012

In this open–label trial, among APOE ε4 non–carriers, the authors observed stabilization of cognition and improvement in executive function among treated individuals compared with non–treated individuals. Among APOE ε4 carriers, cognitive stabilization was evident for treated individuals whereas a cognitive decline was observed in non–treated individuals. These findings provide additional evidence for potential therapeutic efficacy of nilvadipine in treating Alzheimer's disease.

Print Article Summary Cat 2 CME Report